Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of once-weekly lonapegsomatropin in adults with growth hormone deficiency
2021-004313-39Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Apr 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lonapegsomatropin in adult onset growth hormone deficiency (AGHD) and growth hormone deficiency (GHD), sponsored by Ascendis Pharma. Started Apr 2022; status: completed.
02
Drugs
lonapegsomatropin
03
Conditions
adult onset growth hormone deficiency (AGHD)growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2021-004313-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004313-39.